RE:RE:Investors need to believe in future revenues...Thanks Reconsider...
Reconsider said '' I doubt IBRX(ImmunityBio) SP would have reached US40.00 without the stimulus checks''.
The first stimulus checks for US90 million ....
2020-06-29 | NantKwest Announces Closing of $90.7 Million Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares | NDAQ:IBRX | Press Release Came into the picture in June, 29,2020, the ImmunityBio SP was already at
US14.00. The second and biggest stimulus check for US470 million...
2021-12-20 | ImmunityBio Announces Completion of $470 Million Post-merger Financing to Fund Late-stage Cancer Clinical Trials, Phase 3 of COVID T-Cell Universal Boost Vaccine Trial and Provides Update on Bladder Cancer BLA Filing | NDAQ:IBRX | Press Release This very big stimulus check did not influence the SP, as in Dec,2021 the SP had already reached US40.00,
10 months ago. My post was about the fact that a 37months long maintenance therapy that doesn't even cure the cancer did reach US40.00 for whatever reasons.
I agree with you, after the FDA BTD approval of TLT-Ruvidar the SP will not reach US40.00....
But there are two major factors playing big time in favor of TLT-Ruvidar...
1)- ImmunityBio-Anktiva is a 37 months long maintenance therapy that doesn't even cure the cancer.
-TLT-Ruvidar is a ''one and done treatment'' that can cure the cancer, is 100% safe, and has the best CR% of all the FDA approved treatments for BCG resistant patients.
2)- ImmunityBio has a huge 700 million shares out.
-TLT has only 235-335 million shares out.
With the ways the stock market sometime react toward good news about new and efficient cancer treatments, with these two major factors playing big time in favor of TLT-Ruvidar, nobody know to were the SP will climb after the FDA BTD approval of TLT-Ruvidar, maybe not US40.00...But...????
reconsider wrote: Great analysis Wildbird, but it is also important to note that IBRX rise to stardom was mostly fueled by a super liquid market post covid-19 crash (for instance, GME short squeeze happened on Jan 21). I doubt that IBRX would have reached $40 without the stimulus checks, market volatility and stonk investors. The conditions today are much different, although anything is possible. Cheers to an unlikely $40 a share for TLTFF!